Shane DiGiovanna Act
Summary
What This Bill Does
The Shane DiGiovanna Act directs the Secretary of Health and Human Services to begin a nationwide two-year Medicaid demonstration no later than one year after enactment. During the demonstration, state Medicaid plans and waivers must treat specified items and services for epidermolysis bullosa wound care as covered medical assistance for people in the mandatory eligibility categories referenced by section 1902(a)(10)(A)(i) of the Social Security Act.
Required coverage includes over-the-counter antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, antiseptics, zinc oxide, antibiotic ointments, and necessary wound-care supplies. Covered supplies include primary and secondary dressings, gauze, and bandage retainers. Within one year after the demonstration ends, HHS must report to Congress on Medicaid spending, treatment costs avoided, health outcomes compared with the pre-demonstration period, and recommendations for preventing hospitalizations related to epidermolysis bullosa.
Who Benefits and How
Medicaid beneficiaries with epidermolysis bullosa benefit from mandatory coverage of medicines and wound-care supplies that may otherwise create recurring out-of-pocket costs. Their caregivers benefit from more predictable access to dressings, gauze, ointments, pain relievers, and related supplies. Wound-care suppliers and over-the-counter medicine manufacturers may gain Medicaid-funded demand during the demonstration.
Who Bears the Burden and How
State Medicaid programs must add the listed products and services to covered medical assistance nationwide for two years and process resulting claims. Federal and state Medicaid accounts bear the added reimbursement cost, partly offset if better wound care avoids expensive treatment or hospitalization. HHS Medicaid demonstration staff must launch and oversee the program, gather spending and outcome data, compare results, and report to Congress.
Key Provisions
- Requires the nationwide demonstration to begin within one year.
- Runs the mandatory coverage demonstration for two years.
- Covers eligible Medicaid beneficiaries receiving treatment for epidermolysis bullosa.
- Includes antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, antiseptics, zinc oxide, and antibiotic ointments.
- Includes primary and secondary dressings, gauze, bandage retainers, and other necessary wound-care supplies.
- Requires evaluation of Medicaid expenditures and avoided treatment costs.
- Requires comparison of health outcomes with the pre-demonstration period.
- Requires hospitalization-prevention recommendations within one year after the demonstration ends.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Requires a nationwide two-year Medicaid demonstration that covers specified over-the-counter medicines and wound-care supplies for eligible people with epidermolysis bullosa and directs HHS to evaluate spending, outcomes, and hospitalization prevention.
Key Policy Areas
Healthcare, Medicaid, Rare Disease, Prescription Drugs, Medical Supplies, Program Evaluation
Primary Purpose
Requires a nationwide two-year Medicaid demonstration that covers specified over-the-counter medicines and wound-care supplies for eligible people with epidermolysis bullosa and directs HHS to evaluate spending, outcomes, and hospitalization prevention.
Policy Domains
Section 2 nationwide Medicaid wound-care demonstration
Identified Gains
- Medicaid beneficiaries with epidermolysis bullosa
- Caregivers purchasing wound-care supplies
- Wound-care supply manufacturers
- Over-the-counter medicine manufacturers
Identified Costs
- State Medicaid coverage administrators
- HHS Medicaid demonstration staff
- Federal Medicaid financing accounts
- State Medicaid financing accounts
- Congressional Medicaid oversight staff
Sponsors
Legislative Progress
In CommitteeSponsor introductory remarks on measure. (CR H2535)
Referred to the House Committee on Energy and Commerce.
Introduced in House
Mr. Landsman introduced the following bill; which was referred to …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Caregivers purchasing wound-care supplies, Medicaid beneficiaries with epidermolysis bullosa
State Medicaid coverage administrators, State Medicaid financing accounts
Federal Medicaid financing accounts, HHS Medicaid demonstration staff
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary"
- → Secretary of Health and Human Services
- "state_plan"
- → State Medicaid plan or waiver program
- "covered_individual"
- → Medicaid beneficiary in a mandatory eligibility category receiving epidermolysis bullosa treatment
Key Definitions
Terms defined in this bill
Individuals described in Social Security Act section 1902(a)(10)(A)(i) receiving epidermolysis bullosa treatment.
Listed over-the-counter medicines plus necessary dressings, gauze, bandage retainers, and other wound-care supplies used for epidermolysis bullosa.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology